Cell-depleting agents assessment in preclinical models
BRGSF-HIS & hFcγR to assess cell depletion
Depletion of undesirable immune cells has shown to be a promising approach to treat cancer. B-cell-depleting antibodies such as rituximab are often used to treat patients with lymphoma and was shown to improve patients’ survival. Cell depletion can be triggered by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). ADCP and ADCC activities are mediated by Fcγ receptors (FcγR) expressed on immune cells such as natural killer (NK) and macrophages. Translatable assessment of cell-depleting agents in preclinical models requires the presence of functional immune cells and expression of FcγR receptors. Importantly, FcγR expression in mouse and human are distinct, thus increasing the complexity of depleting antibodies assessment studies in preclinical models. Herein, we described two preclinical humanized models for assessment of cell-depleting agents.
Related products
Catalogue product
Customized product
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe